# Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy

> **NCT01720901** · PHASE4 · SUSPENDED · sponsor: **Betta Pharmaceuticals Co., Ltd.** · enrollment: 20 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Icotinib

## Key facts

- **NCT ID:** NCT01720901
- **Lead sponsor:** Betta Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2013-02
- **Primary completion:** 2015-12
- **Final completion:** 2016-12
- **Target enrollment:** 20 (ESTIMATED)
- **Why stopped:** Accrual limitations
- **Last updated:** 2015-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01720901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01720901, "Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01720901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*